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Abstract 
Peptides are of great interest to be used as vaccine antigens due to their safety, ease of 
manufacturing and specificity in generating immune response. There have been massive 
discoveries of peptide antigens over the past decade. However, peptides alone are poorly 
immunogenic, which demand co-administration with strong adjuvant to enhance their 
immunogenicity. Recently, fibril-forming peptides such as Q11 and lipoamino acid-based 
carrier have been identified to induce substantial immune responses when covalently linked 
to peptide epitope. In this study, we have incorporated either Q11 or lipoamino acids to a 
peptide epitope (J14) derived from M protein of Group A Streptococcus to develop self-
adjuvanting vaccines. J14, Q11 and lipoamino acids were also conjugated together in a single 
vaccine construct in an attempt to evaluate the synergy effect of combining multiple 
adjuvants. Physicochemical characterization demonstrated that the vaccine constructs folded 
differently and self-assembled into nanoparticles. Significantly, only vaccine constructs 
containing double copies of lipoamino acids (regardless in conjugation with Q11 or not) were 
capable to induce significant dendritic cells uptake and subsequent J14-specific antibody 
responses in non-sizes dependent manners. Q11 had minimal impact in enhancing the 
immunogenicity of J14 even when it was used in combination with lipoamino acids.  These 
findings highlight the impact of lipoamino acids moiety as a promising immunostimulant 
carrier and its number of attachment to peptide epitope was found to have a profound effect 
on the vaccine immunogenicity. 
 
 
 
 
 
 
 
 
 
  
Graphical Abstract 
 
Figure caption: A B-cell epitope was incorporated into three potentially self-adjuvanting 
vaccine delivery systems and self-assembled into nanoparticles. The presence of two lipids 
moieties was the minimal requirements for the vaccine candidates to induce strong immune 
responses in mice. 
 
 
 
 
 
 
  
1. Introduction  
Vaccine is the most successful medical intervention towards the control of many infectious 
diseases. The conventional vaccine commonly consists of inactivated pathogen or live 
attenuated pathogen. However, unwanted side effects such as allergies, autoimmune 
responses and inflammation are often associated with the use of conventional vaccines.1,2 In 
consequence, modern vaccine research has been shifted towards developing subunit vaccines 
which contain minimal microbial components that offer a safer alternative to the whole 
pathogens approach. Subunit vaccines are generally composed of one or multiple proteins 
derived from the pathogens. Instead of using whole proteins in vaccine formulation, it is 
possible to isolate individual epitopes within these proteins and develop peptide-based 
antigens. Peptides offer several advantages over proteins as they can be easily synthesized, 
purified and are eligible to elicit specific immune responses.1,3 However, peptides alone are 
weakly immunogenic and require co-administration with strong immunoadjuvants to induce 
the desired and robust immune responses. Vast amounts of adjuvants have been investigated 
to be used in mixture with peptide antigens, but majority of them failed to meet the safety 
requirement for clinical routine. This situation has necessitated the pursuit of self-adjuvanting 
vaccine which eliminates the use of external adjuvants that are potentially toxic.4-6 
Recently, it has been found that a short fibrillized peptide, Q11 (QQKFQFQFEQQ) 
covalently conjugated to peptide epitopes induced humoral and cellular immune responses.7-9 
The ovalbumin peptide 323-339 (OVA323-339)-Q11 conjugate raised antibody titers in a 
comparable level to the mixture of OVA323-339 with complete Freund’s adjuvant (CFA) in 
mice.7 It was hypothesized that the Q11 peptide self-assembled into fibrillar network with the 
capability to display the OVA epitope on its surface in a repetitive manner (Figure 1A). It 
was also established that Q11 was not immunogenic on its own, thus would be suitable to be 
used for self-adjuvanting vaccine delivery system. Another strategy towards the development 
of self-adjuvanting vaccine is the conjugation of immunostimulatory lipids to peptide 
antigens. Lipidation of antigenic peptide with synthetic lipids such as lipoamino acids 
(LAAs) has been widely studied (Figure 1B).10-12 Previous data suggested that LAAs with 16 
carbon atoms (C16) were optimal for inducing strong humoral immunity that biased towards 
Th2 response (with predominant IgG1 production), once conjugated to B cell peptide 
epitopes.4,10,13,14 It has been recognized that LAAs may induce the activation of antigen 
presenting cells (APCs) by acting as a toll-like receptor-2 (TLR2) agonist.15,16 
  
 
 
 
Figure 1. The schematic (A) presentation of Q11 peptide that self-assembles into fibril which 
allows repetitive display of peptide epitope on its surface. Schematic (B) presentation of a 
lipopeptide construct based on lipoamino acids. Multiple epitopes (h) can be attached by 
using Lysine as a branching unit. The convention naming of the lipoamino acids are based on 
the total number of carbon atoms in the molecule (e.g. C16 Laa; n=13). The subscript “m” 
indicates the number of lipoamino acids attachment in the construct. 
 
In present work, we have evaluated the applicability of Q11 and LAAs C16 as an adjuvanting 
moiety to a model antigen named J14. J14 is a 29-mer chimeric peptide, 
KQAEDKVKASREAKKQVEKALEQLEDKVK which contains a B cell epitope 
(highlighted in bold) derived from the M-protein conserved region of Group A Streptococcus 
(GAS).17 The 14 amino acid GAS M-protein sequence is enclosed within alpha-helix 
promoter sequence to preserve its native conformation which is required to induce an 
antigen-specific humoral response. The discovery of J14 has been driven by the fact that 
antibodies against whole M-protein have the ability to cross-react with human tissues which 
resulted in autoimmune disease.18 J14 eliminate the unwanted cross-reactivity consequence of 
M-protein, thus represent an ideal model for the needs of peptide-based subunit vaccine. 
  
Antibodies elicited by J14 were capable to confer protection against broad spectrum of GAS 
serotypes only when delivered with strong adjuvants (e.g CFA) or bound to appropriate 
delivery platform.19,20 Currently, many efforts have been made towards the development of 
vaccine delivery systems that utilizes J14 as a major protective epitope.21-23  
 
Herein, several potentially self-adjuvanting vaccine candidates incorporating J14 conjugation 
to Q11 or LAAs C16 (either single or double copies) have been synthesized (Figure 2). It has 
been postulated that incorporation of two or more self-adjuvanting moieties may produce a 
greater immunogenicity effect of the vaccine antigen than any single moiety.24-26 Thus, J14 
has also been conjugated to both Q11 and single/double C16 moiety in an attempt to evaluate 
the synergy effect of combining multiple adjuvants in a single vaccine construct. Vaccine 
constructs have been characterized by dynamic light scattering (DLS), transmission electron 
microscopy (TEM) and circular dichroism (CD) spectroscopy. The ability of the vaccine 
candidates to induce uptake by professional APCs such as dendritic cells (DCs) and 
macrophages were also investigated. Finally, vaccine candidates were administered 
subcutaneously in B10.BR mice to evaluate their capabilities in inducing the systemic J14-
specific IgG antibody production by using prime-boost immunization regimen.  
  
  
Figure 2. Structures of synthetic peptide vaccine constructs 1-5. The peptide vaccines were 
developed based on three components: the B-cell epitope (J14), a fibril-forming peptide 
(Q11) and a lipid moiety featuring lipoamino acids C16. 
 
 
 
 
 
2. Results 
2.1 Synthesis and physicochemical characterization of vaccine constructs 
Each peptide-based vaccine constructs (1-5, Figure 3) was synthesized on p-
methylbenzhydrylamine (pMBHA) resin by using stepwise solid-phase peptide synthesis via 
tert-butoxycarbonyl (Boc) chemistry.27 The N-terminal of the peptide constructs was 
acetylated. A hydrophilic spacer Ser-Gly-Ser-Gly was inserted between the J14 and Q11 
domains, with the J14 domain positioned at N-terminus to provide structural similarity to the 
reported work based on ligand-bearing Q11 derivatives.7,8 Likewise, Ser-Ser residues were 
included between the peptide domain and two lipidic moieties C16 as previously reported.28-
30
 All of the compounds were successfully synthesized with purity greater than 95% after 
purification by RP-HPLC. 
Most B cell peptide epitopes are required to adopt similar folded conformations of their 
native protein for efficient presentation to B cells. In regard to this prerequisite, the secondary 
structure of the vaccine constructs has been investigated. The circular dichroism (CD) 
analysis was performed immediately after dissolving the compounds (day 0) and after two 
days incubation period (day 2) (Figure 3). CD spectra of Q11 alone displayed a minimum 
peak at 228-230 nm, an indicatory to β-sheet or β-turn conformation. The spectrum data was 
consistent with the spectra of Q11 and its derivatives that have been previously reported.7,31 
The Q11 peptide possessed higher degree of β-sheet/β-turn structure in day 2 compared to 
day 0. This suggests that the arrangement of Q11 peptide into a β-sheet rich fibrillar network 
was time-dependent. However, there were no difference observed in terms of the spectra 
  
obtained for the vaccine constructs 1-5 in day 0 and day 2. Spectra of construct 3 (J14-Q11) 
suggested rather random coils than β-sheet structure which characterized by a minimum peak 
at 204 nm. Constructs 4 and 5 which contained J14 conjugated to lipid moieties (either single 
or double copies of C16) possessed a helix structure (negative bands at 208 nm and 222 nm). 
This data demonstrated that the conjugation of lipid moieties to J14 induced α-helical 
conformation. Vaccine constructs 1 and 2 that possess both fibrilizing peptide and LAAs C16 
moiety was expected to adopt a mixture of helical and β-sheet/β-turn secondary structure. 
However, these compounds have higher propensity towards helical conformation with a 
shallow minimum peaks around 208nm and 222nm. The helical structure attained by vaccine 
constructs 1, 2, 4 and 5 is at a comparable degree to that previously reported with other self-
adjuvanting delivery system for peptide-based GAS vaccines.22,32 
       
 
Figure 3. CD spectra of vaccine constructs 1-5 and Q11 that analyzed immediately after 
formulation in PBS (A) and after 2 days incubation in PBS.   
Size of vaccine particle has a significant influence on its uptake by APCs and contributes to 
the type or magnitude of the immune responses.2,24 The size of the vaccine constructs 1-5 in 
aqueous media was analyzed by dynamic light scattering (DLS) and transmission electron 
microscopy (TEM, Figure 4). Size analysis of the individual vaccine constructs was 
summarized in Table 1. The particle size distribution by number as characterized by DLS of 
vaccine constructs 1, 2 and 5 are within the range of 10-70 nm. Particle size of vaccine 
constructs 3 and 4 could not be determined by DLS due to the high polydispersity of the 
particles formed. 
  
 
Table 1. Particle size analysis of vaccine constructs 1-5. 
Vaccine Construct 
Particle size analysis (nm) 
DLS  TEM 
1 13.3 ± 0.9 10-20 
2 10.1 ± 1.3 10-30 
3 Highly polydisperse 20-250 
4 Highly polydisperse 40-300 
5 63.1 ± 5.1 35-100 
 
TEM showed that vaccine constructs 1-5 formed particles in aqueous solution (Fig. 4). The 
diameter range of the particles was consistent with the size measured by DLS (Table 1). The 
Q11 peptide appeared to have a dense and long fibrillar network, with the fibril thickness was 
found to be approximately 20 nm by TEM. By TEM, vaccine construct 3 that is composed of 
J14 and Q11 conjugation appeared to adopt a mixture of cluster-like nanoparticles with 
shallow fibrils-like linkage. However, the nanoparticles were more dominant than the fibril-
like linkage as shown in TEM image of construct 3 (Fig. 4C). Consistently, J14 conjugation 
to either single or double copies of C16 (4 and 5) aggregated to form a nanoparticles as 
observed by TEM (Fig. 4 D, E), which was in good agreement with other reported 
lipopeptides vaccines morphology.33,34 
  
 
Figure 4. Transmission electron microscopy photograph of the synthesized vaccine 
constructs, (A) 1 (bar 200nm), (B) 2 (bar 200nm), (C) 3 (bar 200nm), (D) 4 (bar 500nm), (E) 
5 (bar 500nm), (F) Q11 (bar 200nm). 
2.2 Uptake of vaccine constructs by dendritic cells and microphages 
Uptake of the vaccine constructs 1-5 by dendritic cells (DCs) and macrophages was 
determined by incubating murine splenocytes with fluorescent dyes (dil)-labelled compounds. 
The resultant cells-associated fluorescence was measured by flow cytometry. Overall, uptake 
of the vaccine constructs 1-5 was biased towards DCs than macrophages (Fig. 5). Vaccine 
constructs 1 and 4 were shown to induce a significant uptake by DCs (Fig. 5A). Otherwise, 
vaccine constructs 2, 3 and 5 failed to be taken up efficiently by DCs as there was no 
significant difference in uptake compared to PBS. Similar to DCs, macrophages were able to 
uptake only vaccine constructs 1 and 4 in an efficient manner. This data demonstrates that 
vaccine constructs containing double copies of LAAs C16 were capable to be taken up 
efficiently by the APCs with a favour towards dendritic cells than macrophages. Clearly, a 
single copy of C16 was insufficient to mediate uptake by either DCs or macrophages (Fig. 5; 
vaccine construct 4 vs 5, p > 0.05). As investigated, vaccine construct 3 that is comprised of 
J14-Q11 conjugated was not captured by either DCs or macrophages. Moreover, vaccine 
  
formulation possessing Q11 and double copies of lipoamino acids C16 (construct 1) has 
lower uptake by DCs/macrophages than construct 4 that comprise of J14 conjugated to 
double copies of LAAs C16 (Figure 5; vaccine construct 1 vs 4, p < 0.01). Thus, the 
inclusion of fibril-forming peptide (Q11) in the vaccine formulation did not contribute to the 
stimulation of antigen presentation to neither dendritic cells nor macrophages.  
 
 
Figure 5. Uptake of vaccine constructs (1-5) by DCs (A) and macrophages (B). Dextran was 
used as positive control. Bars represent the mean and standard deviations of the percentage 
cells marker positive for each group corresponds to either DCs or macrophages cells uptake 
(ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001 by one-way ANOVA followed by 
Turkey post hoc test between groups as indicated). 
 
2.3 Evaluation of antibody response to vaccine constructs 
Immunological evaluation of vaccine constructs 1-5 was executed in B10.BR mice by using a 
prime-boost vaccination strategy. The positive control group of mice was immunized with 
J14 emulsified in complete Freund's adjuvant (CFA), whereas the negative control was 
treated with PBS. Serum was collected 9 days after the final boost. Additional group of mice 
were injected with Q11/CFA mixture. There were no IgG levels raised against J14 detected in 
sera from this group, indicated that Q11 was not cross-reacted with J14. Among the vaccine 
constructs, 1 and 4 elicited a significant level of J14-specific IgG titers (Fig. 6).  The levels of 
  
IgG titers induced by these constructs were comparable to mice immunized with J14/CFA 
emulsification (p > 0.05). Vaccine construct 1 was comprised of J14, Q11 and two copies of 
LAAs C16 while construct 4 was consisted of J14 conjugated to double copies of C16. Even 
though higher IgG titers were observed for vaccine construct 1 in comparison to 4, the 
difference was not statistical significant. These data suggested that the combination strategy 
between Q11 and lipidic moieties (C16) as built-in immunoadjuvant has minimal effect in 
inducing antibody productions.  
Constructs 2, 3 and 5 were unable to induce significant level of IgG productions (Fig. 6). 
Numbers of lipid attachments contribute significantly to the J14-specific IgG productions 
(Fig. 6; vaccine construct 1 vs 2, p < 0.001). Similarly, compound 5 that have one C16 less 
than compound 4 were found to be ineffective in eliciting IgG response. Taken together, 
these data suggested that minimally two copies of C16 were required to induce significant 
IgG titers against J14 regardless with the presence of Q11. It has also been demonstrated that 
Q11 failed to induce immune response against J14. Mice administered with construct 3 (J14-
Q11) did not induced any antibody productions. 
 
 
Figure 6. J14-specific serum IgG antibody titers present in the final bleed after immunization 
with vaccine constructs 1-5 in B10.BR mice, as analysed by ELISA. Each point represents 
individual mice; a bar represents the mean antigen-specific serum IgG antibody titers. 
  
Statistical analysis was performed using one-way ANOVA followed by Turkey post hoc test 
between groups as indicated (ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001). 
3. Discussions 
Lipid moieties conjugated to antigenic peptide have been used extensively to generate 
substantial immune responses without the need of external adjuvants.35 The synthesis of lipid 
moieties are usually complex and its conjugation to peptide are often difficult to perform. 
Lipid moieties based on LAAs can overcome these restrictions. LAAs represent structurally 
unique molecules, as they are synthetics amino acids featuring alkyl side-chain.36 This nature 
enables them to be incorporated easily to any known peptide epitope via conventional 
peptide-coupling procedure, such as solid-phase peptide synthesis. The length of alkyl side-
chain can be modified to enhance peptide immunogenicity. Recently, attachment of the short 
self-assembling amino acids sequence namely Q11 to a peptide epitope’s C terminus was 
found to be successful in inducing significant immune responses.7,8,37 Herein, fibril-forming 
peptide (Q11) and LAAs C16 have been evaluated for their application to be used as built-in 
adjuvants towards the development of self-adjuvanting vaccine against GAS (Fig. 2). The 
potential synergy effects from the conjugation of Q11 and LAAs C16 in single construct have 
also been investigated. Vaccine candidates incorporating J14 conjugated to Q11 and/or LAAs 
C16 (single/double copies) created short polypeptides that were easily synthesized on a resin 
via conventional Boc-SPPS protocol. 
 Conjugation of lipid moieties to peptides (lipopeptides) prompts particle formation in 
aqueous environment.23,33 Similarly, vaccine constructs (1, 2, 4 and 5) encompassed of LAAs 
C16 (single/double copies) formed nanoparticles as determined by DLS and TEM (Table 1). 
Extreme particles size distribution of vaccine constructs 3 and 4 were illustrated in TEM 
images where their size ranging from 20 nm – 300 nm. Self-assembly of lipopeptides into 
particles may exhibit pathogen-like property by allowing antigens presentation in a 
multivalent format which may increase the chance of being recognized by APCs. Constructs 
with double copies of LAAs C16 (construct 4) have the tendencies to form larger particles 
than construct containing single copy of C16 (construct 5). This observation can be explained 
by the higher lipophilicity characteristic exhibited by constructs possessing two LAAs. 
Lipopeptides with greater hydrophobicity may increase their propensity to self-assemble into 
larger particles as previously observed.33 However, constructs 1 and 2 bearing Q11 and 
double or single copy of LAAs C16, respectively, formed small nanoparticles indicating 
  
significant influence of Q11 peptide on the constructs morphology. The stimulation of 
immune response is initiated by the uptake of the vaccine antigens by APCs. The size of the 
vaccine particle has great influence in its mechanism of uptake. Large vaccine particles (> 0.5 
µm) are predominantly captured by macrophages while smaller particles (20-100 nm) are 
generally taken up by DCs.24,38 Consistently, the synthesized vaccine constructs were 
primarily taken up by DCs than macrophages (Fig. 5). This was largely due to their particle 
size that falls within 10-300 nm as determined by DLS and TEM (Table 1). Our result 
suggests that at least double copies of LAAs C16 were required to induce optimal DCs 
uptake. Multiple copies of LAAs-based adjuvanting moiety in Lipid Core Peptide (LCP) 
technology were found to induce the activation of toll-like receptors 2 (TLR2).30,39 This 
explains the significant uptake of vaccine constructs 1 and 4 by dendritic cells that possess 
double copies of LAAs C16 as adjuvanting constituents. Therefore, targeting dendritic cells 
through toll-like receptor represents a feasible option for enhancing antigen uptake by these 
cells. 
Immunization with vaccine construct 3 that comprised of J14-Q11 conjugation failed to 
induce significant titers of IgG. The present data was inconsistent with the previous report 
that utilized Q11 as immune adjuvant. This outcome can be explained by the different dosage 
used for immunization. In this work, mice immunized with J14-Q11 received a 10 times 
lower dose concentration than the previously reported immunization with Q11 conjugation to 
either OVA or malaria peptide antigen (NANP)3.7,8 The concentration used in present study 
was similar to that previously reported for other peptide-based vaccine evaluation in vivo that 
utilized J14 as antigen.21,23,40 Unlike the OVA-Q11 and (NANP)3-Q11 conjugates, J14-Q11 
was incapable to induce visible β-sheet conformation and unable to  form a dense fibrillar 
network as observed by CD spectroscopy (Fig. 3) and TEM (Fig. 4C) respectively. The 
disruption of fibril formation could also lead to the loss of adjuvanting activity of Q11. It has 
been recognized that peptide fibrillization may improve the peptide stability against 
enzymatic degradation, which would provide a ‘depot effect’ that elongates the residence 
time of peptide antigen at the injection site for efficient uptake by dendritic cells. In addition, 
epitope fibrillization may also facilitate phagocytosis and stimulation of antigen presenting 
cells. Apparently, the synthesized J14-Q11 conjugate predominantly self-assembled into 
nanoparticles as determined by TEM. Thus, these suggest that fibrillized peptide such as Q11 
is not a generic adjuvant system for peptide-based antigen. On the whole, the fibrillar 
  
platform-based adjuvant has a minimal dose-sparing effect as high dose was required to 
exhibit its immunogenicity effect. 
In light of this work, mice immunized with constructs 1 and 4 were able to raise high titers of 
J14-specific systemic IgG in similar level to the peptide epitope (J14) that was adjuvanted 
with CFA. Both of the compounds consists two copies of LAAs C16 with one of them was 
conjugated along with Q11. Adjuvant-combination strategy between LAAs C16 and 
fibrillization peptide (Q11) produced insignificant synergy effects towards improving the 
immunogenicity of J14 as there is no significant difference between the antibody titres for 
vaccine constructs 1 and 4. However, constructs that contains single copy of C16 (2 and 4), 
regardless with the presence of Q11 were found to be ineffective in inducing systemic IgG 
titres. These findings suggest that the number of lipid moieties (C16) attachment have a 
profound effect on the vaccine immunogenicity. There is no observable correlation between 
size and the different immunogenicity of vaccine constructs, indicating that size have 
minimal influence in inducing antibody productions. 
Overall, lipidation of antigenic peptides is a more viable strategy than the fibrillar platform in 
enhancing immune response of the targeted peptide antigen. Fibrillization peptide such as 
Q11 required high dose to exhibit its adjuvanting effect compared to antigenic peptide 
adjuvanted with lipidic moieties such as LAAs.  
 
 4. Conclusion 
In this study, the synthesis, characterization and immunological evaluation of self-
adjuvanting vaccine constructs against GAS that utilized fibrillized peptide (Q11) and lipidic 
moiety (C16) as built-in immunoadjuvants have been reported. Lipidation of the antigenic 
peptide (J14) with double copies of LAAs C16 were found to be the minimal requirement to 
stimulate substantial antibody titers in mice. Moreover, two copies of LAAs C16 have been 
demonstrated to be essential in inducing the uptake by DCs. At similar dosage, Q11 was 
incapable to induce immune response against J14 B cell epitope or in enhancing vaccine 
immunogenicity when it was used in combination with two copies of LAAs C16 as 
adjuvanting constituent. However, the immune responses elicited were not dependent on the 
size of the vaccine constructs. Taken together, these findings provide insights towards the 
development of self-adjuvanting vaccine based on LAAs C16 as built-in immunoadjuvant. 
  
The constructed vaccine candidates are relatively easy to produce, well chemically defined 
and cost-effective in terms of commercial perspective which makes them more valuable for 
further research to satisfy clinical application. 
 
5. Materials and method 
5.1 Materials 
Protected L-amino acids and pMBHA resin were purchased from Novabiochem 
(Laufelfingen, Switzerland) and Mimotopes (Melbourne, Australia). Peptide synthesis grade 
dichloromethane (DCM), methanol, N, N-diisoproylethylamine (DIPEA), 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) and trifluoroacetic acid (TFA) were purchased from Merck 
(Hohenbrunn, Germany). Solvent for HPLC (acetonitrile (MeCN)) was obtained from 
Labscan (Bangkok, Thailand). All other reagents were purchased at the available purity from 
Sigma-Aldrich (Castle Hill, NSW, Australia). Microwave assisted Boc SPPS was performed 
using a SPS mode CEM Discovery reactor (CME Corporation, Matthews, NC, USA). HF 
cleavage was carried out by using a Kel-F HF apparatus (Peptide Institute, Osaka, Japan). 
ESI-MS was performed by using a Perkin-Elmer-Sciex API3000 instrument with Analyst 1.4 
(AppliedBiosystems/MDS Sciex, Toronto, Canada). Analytical RP-HPLC was performed on 
Agilent instrument with 1 mL min-1 flow rate with compound detection at 214 nm. Separation 
was achieved by running gradient mode of 0-100% solvent B (90% MeCN/0.1% TFA) over 
40 minutes with solvent A (0.1% TFA/H2O) using either a Vydac analytical C4 column 
(214TP54; 5µm, 4.6 × 250 mm) or a Vydac analytical C18 column (218TP54; 5µm, 4.6 × 
250 mm). Peptide purification was performed using a preparative RP-HPLC using a Waters 
Delta 600 system with a 10 mL min-1 flow rate with compounds detection at 230 nm. 
Separation were achieved with solvent A and solvent B on either Vydac preparative C4 
column (214TP1022; 10µm, 22 × 250 mm) or a Vydac preparative C18 column (218TP1022; 
10µm, 22 × 250 mm). CD spectra were measured by using a JASCO J-710 
spectropolarimeter. Sizes were analyzed via a Zetasizer Nano ZP instrument (Malvern 
Instrument, UK) via DTS software. Transmission electron microscopy was performed using a 
JEM-1010 transmission electron microscopy (JEOL Ltd, Japan) operated at 100 kV.TEM 
images were analysed using the Analysis® software (Soft Imaging Systems, Megaview III, 
Munster, Germany). 
  
5.1 Peptide synthesis and purification 
Each vaccine constructs (1-5, Fig. 1), J14 and Q11 were synthesized on pMBHA resin (0.28 
mmol of NH2g-1, 0.2 mmol scale) using microwave-assisted (70 °C, 20 watt) solid-phase 
peptide synthesis with HATU/ N,N-diisoproylethylamine (DIPEA) via Boc chemistry as 
previously reported 41. The 2-(tert-butoxycarbonylamino)-D,L-hexadecanoic acid (Boc-C16-
OH) was synthesized according to the protocol described elsewhere.5 Coupling cycles 
consisted of deprotection of Boc group (2 X 1 min treatment with TFA), DMF flow wash and 
then couplings with preactivated amino acid (twice, 5 and 10 minutes). Amino acid (0.64 
mmol, 4.2 equiv) was dissolved in 0.5 M HATU/DMF solution (1 mL, 4.0 equiv) followed 
by the addition of DIPEA (110 µL, 0.68 mmol, 6.2 equiv) to be activated. Each vaccine 
construct (peptide) was acetylated at N-terminus with a mixture of acetic anhydride (0.5 mL, 
5.29 mmol) and DIPEA (0.5 mL, 2.70 mmol) in DMF (9 mL). Peptides were cleaved from 
the resin by treatment with anyhydrous HF 41. Peptides were purified by preparative RP-
HPLC on either a C18 or C4 column. Separation was achieved based on gradient mode 0.1% 
TFA/H2O (solvent A) and 90% acetonitrile/0.1% TFA/H2O (solvent B) over 60 min. The 
purity (>95%) and identity of the compounds were confirmed by RP-HPLC and ESI-MS. The 
lypophilized peptides were stored at -20 °C until further use. 
Vaccine constructs 1 
Yield: 28%. Molecular Weight: 5832.8. [M+3H]3+ m/z 1945.9 (calc. 1945.3), [M+4H]4+ m/z 
1459.5 (calc. 1459.2). [M+5H]5+ m/z 1168.0 (calc. 1167.6). [M+6H]6+ m/z 974.0 
(calc.973.1). tR = 29.05 min (0-100% Solvent B; C4). 
Vaccine constructs 2 
Yield: 30%. Molecular Weight: 5405.2. [M+3H]3+ m/z 1802.6 (calc. 1802.7), [M+4H]4+ m/z 
1352.6 (calc. 1352.3). [M+5H]5+ m/z 1082.2 (calc. 1082.0). [M+6H]6+ m/z 902.2 (calc. 
901.9). tR = 22.97 min, 23.3 min (0-100% Solvent B; C4). 
Vaccine constructs 3 
Yield: 24%. Molecular Weight: 5154.0. [M+3H]3+ m/z 1718.2 (calc. 1719.0), [M+4H]4+ m/z 
1289.5 (calc. 1289.5). [M+5H]5+ m/z 1031.8 (calc. 1032.0). [M+6H]6+ m/z 859.7(calc. 860.0) 
tR = 19.99 min (0-100% Solvent B; C18). 
Vaccine constructs 4 
  
Yield: 28%. Molecular Weight: 4076.9. [M+3H]3+ m/z 1358.8 (calc. 1359.9), [M+4H]4+ m/z 
1020.6 (calc. 1020.2). [M+5H]5+ m/z 816.7 (calc. 816.4). [M+6H]6+ m/z 681.1 (calc. 680.5). 
tR = 29.62 min, 29.80 min (0-100% Solvent B; C4). 
Vaccine constructs 5 
Yield: 22%. Molecular Weight: 3649.3. [M+3H]3+ m/z 1218.2 (calc. 1217.4), [M+4H]4+ m/z 
913.6 (calc. 913.3). [M+5H]5+ m/z 731.5 (calc. 730.9). [M+6H]6+ m/z 609.9 (calc. 609.2) tR = 
23.90 min, 24.19 min (0-100% Solvent B; C4). 
J14 
Yield: 55%. Molecular Weight: 3354.6 [M+3H]3+ m/z 1118.9(calc. 1119.2), [M+4H]4+ m/z 
839.6 (calc. 839.7). [M+5H]5+ m/z 671.4 (calc.671.9). [M+6H]6+ m/z 559.8 (calc. 560.1) tR = 
18.99 min (0-100% Solvent B; C18). 
Q11 
Yield: 23%. Molecular Weight: 1527.7 [M+H]1+ m/z 1528.7 (calc. 1528.1), [M+2H]2+ m/z 
764.3 (calc. 764.9). tR = 17.25 min (0-100% Solvent B; C18). 
 
5.2 Circular Dichroism (CD) Spectroscopy 
CD spectra were measured on a quartz cuvette with a 1mm path length at 23 °C. CD spectra 
analysis data were collected between 198 nm and 260 nm.  Compounds (vaccine constructs 
1-5 and Q11) were analysed as freshly dissolved in PBS and after incubation at 4 °C for 2 
days. Measurements were performed in triplicate with the average subtracted from the blank 
PBS solution. The mean residual ellipticity was calculated as published elsewhere.12 Working 
concentration for each compounds were based on concentration used for animal studies (0.6 
µg/µL). 
5.2 Dynamic Light Scattering (DLS) 
Sizes were analyzed using a non-invasive back scatter system via dynamic light scattering 
technique. Measurements were taken at 25 °C with scattering angle of 173° by disposable 
cuvettes. Particles of the synthesized compounds were preparedin PBS based on 
  
concentration used in animal studies (0.6 µg/µL). The measurements were conducted at least 
three times. 
5.3 Transmission Electron Microscopy (TEM) 
Compounds were dissolved in deionized water to produce working concentrations based on 
in vivo studies. After 2 days of incubation period, compounds were applied to carbon coated 
200 mesh grids and negative-stained with 1% uranyl acetate. Images were taken from a JEM-
1010 transmission electron microscope (JEOL Ltd., Japan) operated at 80 kV. 
5.4 Uptake of Vaccine Construct by Dendritic Cells (DC) and macrophages in in vitro 
model 
Vaccine constructs were incubated in Dil (1,1 dioctadecyl-3,3,3’,3’- 
tetramethylindocarbocyanine perchlorate) labeled compounds with splenocytes to examine 
their dendritic cells and macrophages. CD11c and F4/80 antibodies were used to mark for 
dendritic cells and macrophages respectively and analyzed by flow cytometry. Briefly, mice 
spleens were passed through a cell strainer to obtain single cell suspension, and red blood 
cells were lysed using erylysis buffer (Sigma-Aldrich). The resulting cells were seeded in a 
12-well plate at a density of 2 x 105 cells/well in phenol free IMDM Glutamax medium 
(Gibco®, Life technologies), supplemented with 10% FBS, 50 µM 2-mercaptoethanol 
(Gibco®, Life technologies), 100 U/ml penicillin, and 100 µg/ml streptomycin(Gibco®, Life 
technologies). Dextran-FITC (positive control) or compounds labeled with DiI (Vybrant®, 
Life technologies) were added to the wells and incubated overnight. The adherent cells were 
scraped from the plate and incubated with Fc-block for 20 min at 4 °C, centrifuged and 
resuspended in a buffer containing CD11c (eBioscience) and F4/80 (BioLegend, Pacific 
Heights Blvd, San Diego, CA, USA) antibodies for 30 min at 4 °C. The cells were then 
centrifuged and resuspended in 0.5 mL of FACS buffer (PBS, 0.02% sodium azide, 0.5% 
BSA) and analyzed using LSR II flowcytometer (BD Biosciences). The fluorescence 
intensities of dendritic cells and macrophages treated with PBS were also measured as a 
control. The actual uptake was calculated as the percentage of cells double positive for Dil 
and CD11c or Dil and F4/80. 
 
 
  
5.5 Mice and subcutaneous immunization 
All protocols were approved by the Institute’s ethics committee (Griffith University Research 
Ethics Review Board for Animal-Based Work) in accordance with National Health and 
Medical Research Council (NHMRC) of Australia guidelines. Four to six week-old female 
B10.BR mice (Animal Resource Centre, Western Australia) were used for immunization. 
Mice (n = 5/group) were injected subcutaneously at the tail base on day 0 with 30 µg 
immunogens (vaccine constructs 1-5) in a total volume of 50 µL of sterile PBS. Mice 
received three further boost at 7-day intervals (days 21, 28, and 32) with the same working 
concentration. Positive control received 30 µg of J14 emulsified in a total volume of 50 µL of 
CFA subcutaneously at the tail base. Negative controls were given 50 µL of either PBS or 30 
µg of Q11 in CFA/PBS emulsion. Positive control was boosted with 30 µg of J14 in a total 
volume of 50 µL PBS and the negative control that received PBS alone was boosted with 50 
µL of PBS. Another negative control was boosted with 30 µg of Q11 in a total volume of 50 
µL PBS.  
5.6 Collection of sera 
Blood was collected from the tail artery of each mouse 1 day prior to each injection and 9 
days after the last immunizations. The blood was left to clot at 37 °C for 1 hr and then 
centrifuged for 10 minutes at 3000 rpm to remove clots. Sera were then stored at -20 °C. 
5.7 ELISA for Systemic IgG Antibodies Detection  
Detection of serum IgG antibodies against the J14 epitope was performed using an enzyme 
linked immunosorbent assay (ELISA) as previously reported.41 Briefly, ELISA plates were 
coated with J14 (10 mg/ml) in carbonate coating buffer overnight at 4 °C and blocked with 
150 µL/well of 5% skim milk for 90 minutes at 37 °C.  Serial dilutions of collected sera were 
prepared in 0.5% skim milk /PBS-Tween-20 buffer, starting at 1:100 concentration followed 
by 1:2 dilutions. Absorbance values were read at 450 nm in a microplate reader after the 
addition of secondary antibody (peroxidise-conjugated antimouse IgG) and O-
phenylenediamine. The antibody titer was identified as the lowest dilution that give 
absorbance of more than 3 standard deviations above the mean absorbance of control wells 
(contains normal mouse serum). Statistical analysis (p < 0.05 = statistical significance) was 
performed with one-way ANOVA followed by Turkey post hoc test.  
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